In the CSF, CD4+, and CD8+ T-cells, as well as CD19+ B-cell and CD138+ plasma cells were found lower in NTZ-treated patients compared with untreated MS patients or healthy subjects, this lower rate persisting 6 months after NTZ cessation, but returning to normal levels 14 months after NTZ cessation independently of any clinical or radiological rebound phenomenon (29, 32). Here, CD4 is linked to myeloid sarcoma.